Zoetis Inc. (ZTS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensat... ACCESSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on ZTS
    Zoetis Inc. (ZTS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    11:02a ET May 2 '24 ACCESSWIRE

    NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS). Investors who purchased Zoetis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZTS.

    Investigation Details:

    On April 12, 2024, The Wall Street Journal published an article entitled "What Killed Their Pets? Owners Blame Meds, but Vets Aren't Sure." The article reported that "[h]ealth regulators in the U.S. and Europe . . . are conducting reviews" of the Zoetis-produced drugs Librela and Solensia, respectively used to treat arthritis in dogs and cats, after "receiv[ing] thousands of reports of side effects" from pet owners.

    On this news, Zoetis's stock price fell $12.75 per share, or 7.83%, to close at $149.98 per share on April 12, 2024.

    What's Next?

    If you are aware of any facts relating to this investigation or purchased Zoetis securities, you can assist this investigation by visiting the firm's site: bgandg.com/ZTS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

    There is No Cost to You

    We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

    Why Bronstein, Gewirtz & Grossman:

    Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contact:

    Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller,332-239-2660 | info@bgandg.com

    SOURCE: Bronstein, Gewirtz & Grossman, LLC

    View the original press release on accesswire.com

    COMTEX_451780548/2457/2024-05-02T11:02:29

    ZTS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourag...
    9:47a ET May 2 '24 ACCESSWIRE
    Zoetis Announces First Quarter 2024 Results
    7:00a ET May 2 '24 BusinessWire
    Zoetis Inc. (ZTS) Investigation: Bronstein, Gewirtz & Grossman, LLC E...
    11:01a ET May 1 '24 ACCESSWIRE
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigatin...
    10:03p ET April 30 '24 ACCESSWIRE
    ZTS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourage...
    4:56p ET April 30 '24 Newsfile Corp
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf o...
    4:02p ET April 30 '24 Newsfile Corp
    Zoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impact...
    2:52p ET April 30 '24 GlobeNewswire
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to ...
    12:40p ET April 30 '24 GlobeNewswire
    Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors
    4:30p ET April 1 '24 BusinessWire
    Zoetis to Host Webcast and Conference Call on First Quarter 2024 Fina...
    8:30a ET March 28 '24 BusinessWire

    Market data provided by News provided by